A recent study has been published by investigators at the University of Turin in the peer-reviewed journal Current Oncology. This study focused on the performance of Seravue and the LC-SPIK biomarker in detecting hepatocellular carcinoma (HCC) in a pool of nonalcoholic fatty liver disease (NAFLD) related cirrhosis patients. Here, LC-SPIK had an AUC of 0.841 and significantly outperformed AFP, the most common biomarker used for HCC detection today. Additionally, LC-SPIK did not exhibit a degradation in performance in early-stage HCC patients.
Based on the results, the authors also concluded that the LC-SPIK biomarker was complementary to other biomarkers including AFP and PIVKA-II (DCP), and that there is significant potential for LC-SPIK to be part of a standard multianalyte panel or one enhanced with AI. Overall, we are pleased that a study from an independent third party has validated ImCare Biotech’s own studies and findings around the potential of Seravue and its potential to improve the standard of care for HCC detection and surveillance.
Check out the open-access study in Current Oncology to learn more.
